email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
1261 - 1275
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
Innovent Partners with Synaffix to Create ADC Candidate from Antibody
$5.00
Available
Neurophth Starts China Trial of Gene Therapy for Hereditary Blindness
$5.00
Available
Pulnovo Medical Completes Trial Enrollment for Pulmonary Hypertension Device
$5.00
Available
Hangzhou Jointech Raises $62 Million for Orthopedic Surgery Robots
$5.00
Available
InxMed Says FAK Inhibitor Effective Against Resistance to KRAS Inhibitors
$5.00
Available
Lynk Pharma to Start Trials of Novel Therapy for IBD
$5.00
Available
Nanjing's Triastek Completes $50 Million Round for 3D Printing of Drugs
$5.00
Available
HutchMed/AstraZeneca Approved to Launch Partnered MET Inhibitor in China
$5.00
Available
MindRank Completes $7 Million Angel Round for AI Drug Development
$5.00
Available
Fosun Kite's CAR-T Approved in China for Lymphoma
$5.00
Available
BeiGene's Anti-PD-1 Approved in China for 4th and 5th Indications
$5.00
Available
Asieris Starts EU Arm in Global Trial of Photodynamic Drug-Device Product
$5.00
Available
BeiGene Approved to Launch Brukinsa® for 3rd B-Cell Cancer Indication
$5.00
Available
HutchMed's Surufatinib Approved for 2nd Neuroendocrine Tumor Indication
$5.00
Available
Bioheng Granted US Orphan Drug Status for Universal CAR-T Therapy
$5.00
Available